Australia's Cynata Therapeutics rises on regulatory approval in EU

Cynata Therapeutics

20/03/2024 04:13

** Shares of Cynata Therapeutics  CYP.AX  rise as much as
8.8% to A$0.185, their highest since March 12
    ** Regenerative medicine co says it has received regulatory
and ethics approval in the European Union for its phase 2
clinical trial for high-risk acute graft versus host disease
(GvHD) drug 
    ** GvHD can occur after a bone marrow transplant, where the
donor's immune cells attack the recipient of the transplant 
    ** Stock up 36% YTD, as of last close

 (Reporting by Neha Soni in Bengaluru)
 ((Neha.Soni@thomsonreuters.com))